nach oben

Journal of Nephrology

Erschienen in:

01.04.2017 | Review

Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)

verfasst von: Laura Cosmai, Maurizio Gallieni, Wanda Liguigli, Camillo Porta

Erschienen in: Journal of Nephrology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Since angiogenesis plays a key role in tumor growth, progression and metastasization, anti-vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) agents have been developed over the years as anticancer agents, and have changed, for the better, the natural history of a number of cancer types. In the present review, the renal safety profile of presently available agents targeting either VEGF or VEGFRs will be discussed, together with the peculiarities related to their clinical use in patients with impaired renal function, or even in dialysis. Indeed, renal toxicity (especially, but not exclusively, hypertension and proteinuria) are quite commonly observed with these agents, and may be increased by the concomitant use of cytoxic chemotherapeutics. Despite all the above, kidney impairment or dialysis must not be regarded di per se as reasons not to administer or to stop an active anticancer treatment, especially considering the possibility of a significant survival improvement in many cancer patients treated with these agents.

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186CrossRefPubMed

Neufeld G, Cohen T, Gengrinovitch S et al (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9–22PubMed

McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5(Suppl. 1):3–10CrossRefPubMed

Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359–1364CrossRefPubMed

Doi K, Noiri E, Fujita T (2010) Role of vascular endothelial growth factor in kidney disease. Curr Vasc Pharmacol 8:122–128CrossRefPubMed

Schrijvers BF, Flyvbjerg A, De Vriese AS (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65:2003-17. Nat Rev Drug Discov 3:391–400CrossRef

Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544CrossRefPubMed

Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550CrossRefPubMed

Croom KF, Dhillon S (2011) Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 71:2213–2229CrossRefPubMed

10.

Tanne JH (2011) FDA cancels approval for bevacizumab in advanced breast cancer. BMJ 343:d7684CrossRefPubMed

11.

Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111CrossRefPubMed

12.

Eskander RN, Tewari KS (2014) Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol 132:496–505CrossRefPubMed

13.

Specenier P (2012) Bevacizumab in glioblastoma multiforme. Expert Rev Anticancer Ther 12:9–18CrossRefPubMed

14.

Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499–3506CrossRefPubMed

15.

Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39CrossRefPubMed

16.

Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235CrossRefPubMed

17.

Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673CrossRefPubMed

18.

Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499–508CrossRefPubMed

19.

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124CrossRefPubMed

20.

Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338CrossRefPubMed

21.

Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513CrossRefPubMed

22.

Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068CrossRefPubMed

23.

van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886CrossRefPubMed

24.

Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939CrossRefPubMed

25.

Margolin K, Gordon MS, Holmgren E et al (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19:851–856CrossRefPubMed

26.

Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F (2015) Renal effects of targeted anticancer therapies. Nat Rev Nephrol 11:354–370CrossRefPubMed

27.

Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50:203–218CrossRefPubMed

28.

Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K (2011) Bevacizumab-induced hypertension. Pathogenesis and management. Biodrugs 25:159–169CrossRefPubMed

29.

Stylianou K, Lioudaki E, Papadimitraki E et al (2011) Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. Nephrol Dial Transplant 26:1742–1745CrossRefPubMed

30.

George BA, Zhou XJ, Toto R (2007) Nephrotic syndrome after Bevacizumab: case report and literature review. Am J Kidney Dis 49:e23–e29CrossRefPubMed

31.

Eremina V, Jefferson JA, Kowalewska J et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129–1136CrossRefPubMedPubMedCentral

32.

Sugimoto H, Hamano Y, Charytan D et al (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278:12605–12608CrossRefPubMed

33.

Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799CrossRefPubMed

34.

Zachary I (2001) Signaling mechanism mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol 280:c1375–c1386

35.

Mourad JJ, des Guetz G, Debbabi H, Levy BI (2008) Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19:927–934CrossRefPubMed

36.

Yao SK, Ober JC, Krishnaswami A et al (1992) Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 86:1302–1309CrossRefPubMed

37.

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027CrossRefPubMed

38.

Mancia G, De Backer G, Dominiczak A et al (2007) 2007 ESH-ESC Practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the management of arterial hypertension. J Hypertens 25:1751–1762CrossRefPubMed

39.

Izzedine H, Ederhy S, Goldwasser F et al (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20:807–815CrossRefPubMed

40.

BC Cancer Agency. BC Cancer agency management guidelines. Management guidelines of bevacizumab-related side effects. http://www.bccancer.bc.ca/NR/rdonlyres/6D39414F-EC1A4BE-9ACB-6DE017C9B4C4/19258/managementforbevacizumabsideeffects_1Dec06.pdf. Accessed 22 June 2014

41.

Porta C, Paglino C, Imarisio I, Bonomi L (2007) Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents: the case of sorafenib and sunitinib. Clin Exp Med 7:127–134CrossRefPubMed

42.

Izzedine H, Perazzella MA (2015) Thrombotic microangiopathies, cancer and cancer drugs. Am J Kidney Dis 66:857–868CrossRefPubMed

43.

Blake-Haskins JA, Lechleider RJ, Kreitman R (2011) Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 17:5858–5866CrossRefPubMedPubMedCentral

44.

Porta C, Danova M, Riccardi A, Bobbio-Pallavicini E, Ascari E (1999) Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 74:570–574CrossRefPubMed

45.

Feldman DR, Baum MS, Ginsberg MS et al (2009) Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1432–1439CrossRefPubMedPubMedCentral

46.

Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with Bevacizumab, an antibody against vascular endothelial growth factor: sistematic review and meta-analysis. Am J Kidney Dis 49:186–193CrossRefPubMed

47.

Wu S, Kim C, Baer L, Zhu X (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21:1381–1389CrossRefPubMedPubMedCentral

48.

Zhang ZF, Wang T, Liu LH, Guo HQ (2014) Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS ONE 9:e90135CrossRefPubMedPubMedCentral

49.

Abdel-Rahman O, El Halawani H (2014) Proteinuria in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis. Chemotherapy 60:325–333CrossRefPubMed

50.

Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypert 23:460–468CrossRef

51.

Qi WX, Shen Z, Tang LN, Yao Y (2014) Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. Clin Drug Investig 34:231–240CrossRefPubMed

52.

Wang J, Wang Z, Zhao Y (2015) Incidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies. Clin Drug Investig 35:221–228CrossRefPubMed

53.

Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48:9–17CrossRefPubMed

54.

Qi WX (2013) Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol 71:431–439CrossRefPubMed

55.

Qi WX, He AN, Shen Z, Yao Y (2013) Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 76:348–357CrossRefPubMedPubMedCentral

56.

Macfarlane R, Heng DY, Xie W et al (2012) The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. Cancer 118:365–370CrossRefPubMed

57.

Khosravan R, Toh M, Garrett M et al (2009) Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 50:472–481CrossRefPubMed

58.

Gupta S, Parsa V, Heilbrun LK et al (2011) Safety and efficacy of targeted agents in metastatic kidney cancer patients with renal dysfunction. Anticancer Drugs 22:794–800CrossRefPubMedPubMedCentral

59.

Méndez-Vidal MJ, Martínez Ortega E, Montesa Pino A, Pérez Valderrama B, Viciana R (2012) Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 31(Suppl 1):S19–S27CrossRefPubMed

60.

Garnier-Viougeat N, Rixe O, Paintaud G et al (2007) Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant 22:975CrossRefPubMed

61.

Inauen R, Cathomas R, Boehm T et al (2007) Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Oncology 72:209–210CrossRefPubMed

62.

Masini C, Sabbatini R, Porta C et al (2012) Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int 110:692–698CrossRefPubMed

63.

Josephs D, Hutson TE, Cowey CL et al (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 108:1279–1283CrossRefPubMed

64.

Izzedine H, Etienne-Grimaldi MC, Renée N, Vignot S, Milano G (2009) Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 20:190–192CrossRefPubMed

65.

Porta C, Levy A, Hawkins R et al (2014) Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med 3:1517–1526CrossRefPubMedPubMedCentral

66.

Cosmai L, Porta C, Gallieni M, Perazella MA (2016) Onco-nephrology: a decalogue. Nephrol Dial Transplant 31(4):515–519CrossRefPubMed

Titel: Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)
verfasst von: Laura Cosmai
Maurizio Gallieni
Wanda Liguigli
Camillo Porta
Publikationsdatum: 01.04.2017
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 2/2017
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-016-0311-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Thyroid function and cardiovascular events in chronic kidney disease patients

Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis

Why choose high volume online post-dilution hemodiafiltration?

Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology

A comparison of three induction therapies on patients with delayed graft function after kidney transplantation

Updated genetic testing of Italian patients referred with a clinical diagnosis of primary hyperoxaluria